Literature DB >> 22794351

Treatment of posttraumatic syringomyelia.

Jörg Klekamp1.   

Abstract

OBJECT: This paper presents results of a prospective study for patients undergoing surgery for posttraumatic syringomyelia between 1991 and 2010.
METHODS: A group of 137 patients with posttraumatic syringomyelia were evaluated (mean age 45 ± 13 years, mean follow-up 51 ± 51 months) with pre- and postoperative MRI and clinical examinations presenting in this period and followed prospectively by outpatient visits and questionnaires. Surgery was recommended for symptomatic patients with a progressive course. Short-term results were determined within 3 months of surgery, whereas long-term outcomes in terms of clinical recurrences were studied with Kaplan-Meier statistics.
RESULTS: Three groups were distinguished according to the type of trauma: Group A, patients with spinal trauma but without cord injury (ASIA E, n = 37); Group B, patients with an incomplete cord injury (ASIA C or D, n = 55); and Group C, patients with complete loss of motor function or a complete cord injury (ASIA A or B, n = 45). Overall, 61 patients with progressive symptoms underwent 71 operations. Of these operations, 61 consisted of arachnolysis, untethering, and duraplasty at the trauma level (that is, decompression), while 4 ASIA A patients underwent a cordectomy. The remaining procedures consisted of placement of a thecoperitoneal shunt, 2 opiate pump placements, and 2 anterior and 1 posterior cervical decompression and fusion. Seventy-six patients were not treated surgically due to lack of neurological progression or refusal of an operation. Neurological symptoms remained stable for 10 years in 84% of the patients for whom surgery was not recommended due to lack of neurological progression. In contrast, 60% of those who declined recommended surgery had neurological progression within 5 years. For patients presenting with neurological progression, outcome was better with decompression. Postoperatively, 61% demonstrated a reduction of syrinx size. Although neurological symptoms generally remained unchanged after surgery, 47% of affected patients reported a postoperative improvement of their pain syndrome. After 3 months, 51% considered their postoperative status improved and 41% considered it unchanged. In the long-term, favorable results were obtained for Groups A and C with rates for neurological deterioration of 6% and 14% after 5 years, respectively. In Group B, this rate was considerably higher at 39%, because arachnolysis and untethering to preserve residual cord function could not be fully achieved in all patients. Cordectomy led to neurological improvement and syrinx collapse in all 4 patients.
CONCLUSIONS: The technique of decompression with arachnolysis, untethering, and duraplasty at the level of the underlying trauma provides good long-term results for patients with progressive neurological symptoms following ASIA A, B and E injuries. Treatment of patients with posttraumatic syringomyelia after spinal cord injuries with preserved motor functions (ASIA C and D) remains a major challenge. Future studies will have to establish whether thecoperitoneal shunts would be a superior alternative for this subgroup.

Entities:  

Mesh:

Year:  2012        PMID: 22794351     DOI: 10.3171/2012.5.SPINE11904

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  20 in total

1.  Surgical treatment of multilevel cervical spondylosis in patients with or without a history of syringomyelia.

Authors:  Jörg Klekamp
Journal:  Eur Spine J       Date:  2017-02-11       Impact factor: 3.134

2.  Prophylactic enlargement of the thecal sac volume by spinal expansion duroplasty in patients with unresectable malignant intramedullary tumors and metastases prior to radiotherapy.

Authors:  Ingo Fiss; C Bettag; B Schatlo; K von Eckardstein; I Tsogkas; A Schwarz; C von der Brelie; V Rohde
Journal:  Neurosurg Rev       Date:  2018-11-14       Impact factor: 3.042

3.  The characteristics of posttraumatic syringomyelia.

Authors:  J Krebs; H G Koch; K Hartmann; A Frotzler
Journal:  Spinal Cord       Date:  2015-12-01       Impact factor: 2.772

4.  Post-traumatic syringomyelia refractory to surgical intervention: a series of cases on recurrent syringomyelia.

Authors:  H P Leahy; A A Beckley; C S Formal; G W Fried
Journal:  Spinal Cord Ser Cases       Date:  2015-10-08

5.  Spinal cord untethering and midline myelotomy for delayed, symptomatic post-traumatic syringomyelia due to retained ballistic fragments: case report.

Authors:  Tej D Azad; Joshua Materi; Brian Y Hwang; Dimitrios Mathios; Kurt R Lehner; Landon Hansen; Lydia J Bernhardt; Yuanxuan Xia; Pavan P Shah; Nivedha V Kannapadi; Nicholas Theodore
Journal:  Spinal Cord Ser Cases       Date:  2022-07-12

Review 6.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

7.  [Spinal cord injury and syringomyelia].

Authors:  M Wolf; C H Fürstenberg; S Hähnel; M-A Weber
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

8.  Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients.

Authors:  Ulrika Holmström; Parmenion P Tsitsopoulos; Hjalmar Flygt; Anders Holtz; Niklas Marklund
Journal:  Spinal Cord       Date:  2018-03-27       Impact factor: 2.772

9.  Syringomyelia coexisting with guillain-barre syndrome.

Authors:  Hee-Sang Kim; Dong Hwan Yun; Jinmann Chon; Jong Eon Lee; Min Ho Park; Yoo Jin Han
Journal:  Ann Rehabil Med       Date:  2013-10-29

10.  Rapid progression of acute cervical syringomyelia: A case report of delayed complications following spinal cord injury.

Authors:  Chenghua Yuan; Jian Guan; Fengzeng Jian
Journal:  J Spinal Cord Med       Date:  2020-03-23       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.